CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 8 enrolled
Drug / intervention
[14C]-benzo[a]pyrenedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03318978
NCT03318978Early Ph 1Completed
CompareCT.gov

Benzo[a]Pyrene Ultralow Dose-Response Study

Oregon State University·interventional·Posted Oct 24, 2017·Updated May 22, 2025

In Brief

A Early Phase 1 clinical trial evaluating [14C]-benzo[a]pyrene for Environmental Exposure. Completed, enrolled 8 participants across 1 site.

Detailed Summary

Evaluation of the pharmacokinetics for \[14C\]-benzo\[a\]pyrene (\[14C\]-BaP) and metabolites in plasma and urine over 48 hours following 4 oral doses of 25, 50, 10 and 250 ng (2.7-27 nCi).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEnvironmental Exposure
CountriesUnited States
CollaboratorsNational Institute of Environmental Health Sciences (NIEHS), Lawrence Livermore National Laboratory, Pacific Northwest National Laboratory

Timeline

Early Ph 1CompletedFinished
201820192020202120222023202420252026
First PostedOct 24, 2017
Enrollment StartApr 17, 2018
Primary CompletionJan 1, 2024
Study CompletionFeb 1, 2024
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 8.7 years ago

Interventions

[14C]-benzo[a]pyrenedrug

Oral micro-dose range (25, 50, 100 and 250 ng)